Literature DB >> 10752524

X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males.

Jean Philippe Jais1, Bertrand Knebelmann2, Iannis Giatras2, Mario DE Marchi3, Gianfranco Rizzoni3, Alessandra Renieri3, Manfred Weber4, Oliver Gross4, Kai-Olaf Netzer4, Frances Flinter5, Yves Pirson6, Christine Verellen6, Jörgen Wieslander7, Ulf Persson7, Karl Tryggvason8, Paula Martin8, Jens Michael Hertz9, Cornelis Schröder10, Marek Sanak11, Sarka Krejcova12, Maria Fernanda Carvalho13, Juan Saus14, Corinne Antignac2, Hubert Smeets15, Marie Claire Gubler2.   

Abstract

Alport syndrome (AS) is a type IV collagen hereditary disease characterized by the association of progressive hematuric nephritis, hearing loss, and, frequently, ocular changes. Mutations in the COL4A5 collagen gene are responsible for the more common X-linked dominant form of the disease. Considerable allelic heterogeneity has been observed. A "European Community Alport Syndrome Concerted Action" has been established to delineate accurately the AS phenotype and to determine genotype-phenotype correlations in a large number of families. Data concerning 329 families, 250 of them with an X-linked transmission, were collected. Characteristics of the 401 male patients belonging to the 195 families with COL4A5 mutation are presented. All male patients were hematuric, and the rate of progression to end-stage renal failure and deafness was mutation-dependent. Large deletions, non-sense mutations, or small mutations changing the reading frame conferred to affected male patients a 90% probability of developing end-stage renal failure before 30 yr of age, whereas the same risk was of 50 and 70%, respectively, in patients with missense or splice site mutation. The risk of developing hearing loss before 30 yr of age was approximately 60% in patients with missense mutations, contrary to 90% for the other types of mutations. The natural history of X-linked AS and correlations with COL4A5 mutations have been established in a large cohort of male patients. These data could be used for further evaluation of therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10752524     DOI: 10.1681/ASN.V114649

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  171 in total

Review 1.  Order and disorder: the role of extracellular matrix in epithelial cancer.

Authors:  Derek Radisky; John Muschler; Mina J Bissell
Journal:  Cancer Invest       Date:  2002       Impact factor: 2.176

2.  Poststreptococcal acute glomerulonephritis can be a risk factor for accelerating kidney dysfunction in Alport syndrome: a case experience.

Authors:  Yoshinori Araki; Azusa Kawaguchi; Nana Sakakibara; Yoshinobu Nagaoka; Tomohiko Yamamura; Tomoko Horinouchi; China Nagano; Naoya Morisada; Kazumoto Iijima; Kandai Nozu
Journal:  CEN Case Rep       Date:  2020-06-26

3.  Clinical utility gene card for: Alport syndrome.

Authors:  Jens Michael Hertz; Mads Thomassen; Helen Storey; Frances Flinter
Journal:  Eur J Hum Genet       Date:  2011-12-14       Impact factor: 4.246

4.  Alport syndrome: About time--treating children with Alport syndrome.

Authors:  Judy Savige
Journal:  Nat Rev Nephrol       Date:  2012-05-29       Impact factor: 28.314

5.  Identification of the NC1 domain of {alpha}3 chain as critical for {alpha}3{alpha}4{alpha}5 type IV collagen network assembly.

Authors:  Valerie LeBleu; Malin Sund; Hikaru Sugimoto; Gabriel Birrane; Keizo Kanasaki; Elizabeth Finan; Caroline A Miller; Vincent H Gattone; Heather McLaughlin; Charles F Shield; Raghu Kalluri
Journal:  J Biol Chem       Date:  2010-09-16       Impact factor: 5.157

6.  Genotype-phenotype correlation in X-linked Alport syndrome.

Authors:  Mir Reza Bekheirnia; Berenice Reed; Martin C Gregory; Kim McFann; Alireza Abdollah Shamshirsaz; Amirali Masoumi; Robert W Schrier
Journal:  J Am Soc Nephrol       Date:  2010-04-08       Impact factor: 10.121

7.  X-linked Alport syndrome associated with a synonymous p.Gly292Gly mutation alters the splicing donor site of the type IV collagen alpha chain 5 gene.

Authors:  Xue Jun Fu; Kandai Nozu; Aya Eguchi; Yoshimi Nozu; Naoya Morisada; Akemi Shono; Mariko Taniguchi-Ikeda; Yuko Shima; Koichi Nakanishi; Igor Vorechovsky; Kazumoto Iijima
Journal:  Clin Exp Nephrol       Date:  2015-11-18       Impact factor: 2.801

Review 8.  [Early diagnosis of chronic kidney diseases].

Authors:  E Schulze-Lohoff; T Matthäus; M Weber
Journal:  Internist (Berl)       Date:  2005-04       Impact factor: 0.743

9.  Sequential expression of type IV collagen networks: testis as a model and relevance to spermatogenesis.

Authors:  Scott J Harvey; Julie Perry; Keqin Zheng; Dilys Chen; Yoshikazu Sado; Barbara Jefferson; Yoshifumi Ninomiya; Robert Jacobs; Billy G Hudson; Paul S Thorner
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

Review 10.  Collagen IV diseases: A focus on the glomerular basement membrane in Alport syndrome.

Authors:  Dominic Cosgrove; Shiguang Liu
Journal:  Matrix Biol       Date:  2016-08-27       Impact factor: 11.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.